Pfizer and BioNTech to Supply the European Union With up to 1 8 Billion Additional Doses of COMIRNATY® pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Pfizer Inc.: Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY
Additional dose deliveries beginning December 2021 through 2023
Pfizer and BioNTech have now committed a total of up to 2.4 billion doses of COMIRNATY to the EC since the beginning of the pandemic
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY
, the companies COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005450/en/
(0)
ISTANBUL, TURKEY and MAINZ, GERMANY,
May 20, 2021(Nasdaq: BNTX) today announced that the BioNTech Europe GmbH has entered into an agreement with Turkey s Ministry of Health to supply 60 million additional doses of the companies COVID-19 vaccine, with an option for an additional 30 million doses. On December 25, 2020, the two companies announced an initial agreement to provide 30 million doses of the Pfizer-BioNTech vaccine to Turkey. This second supply agreement brings the total number of doses to be supplied to Turkey to up to 120 million, all of which will be delivered in 2021. Our goal is to deliver as many doses of our COVID-19 vaccine as possible to people around the world to help end this pandemic, reduce COVID-19-related hospitalisations and return to a normal life. We are grateful to be able to make an important contribution to Turkey s vaccination efforts and for the trust placed in us, said
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®
New agreement to supply 900 million doses to the European Commission with option to request up to an additional 900 million doses Additional dose deliveries beginning December 2021 through 2023 Pfizer and BioNTech have now committed a total of up to 2.4 billion doses of COMIRNATY® to the EC since the beginning of the pandemic Pfizer Inc. and BioNTech SE today announced a new agreement with the European Commission … New agreement to supply 900 million doses to the European Commission (EC), with option to request up to an additional 900 million doses
Search jobs Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years
Data also submitted to European Medicines Agency (EMA) and other global regulators, with additional authorizations expected in coming weeks
NEW YORK & MAINZ, Germany (BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.